Prospective analysis of UGT1A1 promoter polymorphism for irinotecan dose escalation in metastatic colorectal cancer patients treated with bevacizumab plus FOLFIRI as the first-line setting: study protocol for a randomized controlled trial

BACKGROUND: Irinotecan is approved and widely administered to metastatic colorectal cancer (mCRC) patients; however, it can cause severe toxicities including neutropenia and diarrhea. The polymorphisms of genes encoding drug-metabolizing enzymes can play a crucial role in the increased susceptibilit...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Trials
Päätekijät: Yeh, Yung-Sung, Tsai, Hsiang-Lin, Huang, Ching-Wen, Wang, Jui-Ho, Lin, Yi-Wen, Tang, Hsiu-Chih, Sung, Yung-Chuan, Wu, Chang-Chieh, Lu, Chien-Yu, Wang, Jaw-Yuan
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BioMed Central 2016
Aiheet:
Study Protocol
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4727397/
https://ncbi.nlm.nih.gov/pubmed/26811156
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13063-016-1153-3
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia